Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

NextEdge Admin

24 Dec 2024

2 min 16 sec

Eisai,partnership,Alzheimer’s disease,neurodegenerative

Fujirebio and Eisai have advanced their partnership to accelerate the development and commercialization of diagnostic methods for neurodegenerative diseases, including Alzheimer’s disease (AD). Leveraging Fujirebio’s expertise in test reagents for neurodegenerative diseases and Eisai’s experience in dementia therapeutics, the collaboration aims to integrate their respective strengths. Key areas of focus include clinical implementation of diagnostic reagents for plasma phosphorylated tau 217 protein (p-Tau217), development of blood-based biomarker diagnostics, and commercialization of in vitro diagnostics.

This non-exclusive partnership seeks to establish diagnostic technologies addressing high unmet needs in neurodegenerative diseases, with plans to expand these solutions globally. By creating tools that enable earlier and more precise diagnosis, the collaboration strives to improve treatment selection and outcomes for patients, advancing care and management of these conditions.

Fujirebio, part of H.U. Group Holdings Inc., is a global leader in in-vitro diagnostic (IVD) testing with over 50 years of experience. It was the first company to commercialize cerebrospinal fluid (CSF) biomarkers for AD testing and offers a comprehensive portfolio of neurodegenerative disease assays. Fujirebio continues to pioneer innovations in diagnostics worldwide.

Eisai is committed to improving health and reducing disparities under its human health care (hhc) Concept. With a global network, Eisai focuses on developing innovative neurology and oncology treatments. It also supports the United Nations’ Sustainable Development Goals (SDGs) through initiatives to eliminate neglected tropical diseases (NTDs) alongside global partners.